Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Morphine for Chronic Wound Pain
NCT02028923Phase 3
Key facts
- Status
- Terminated
- Start
- Apr 2014
- Primary completion
- Jul 2016
- Countries
- 1
- Sponsor
- Institut Curie
- Modality
- Small Molecules
- Conditions
- painChronic wound
01
Overview
Phase 3, randomised, double-blind trial of morphine hydrochloride in pain and Chronic wound, sponsored by Institut Curie. Primary endpoint: Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg at 11 days. Started Apr 2014; status: terminated.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults with painful chronic wounds (e.g., bedsores, ulcers) and a pain score >= 5 despite systemic analgesics.
04
Endpoints
Primary
Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg
Beyond the preview
Go deeper on NCT02028923.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028923.